When questioned specifically on their anaemia management approach in patients with a history of cancer (of specific interest following the TREAT study), 47 and 49 % of respondents at T1 claimed to consider time in remission and cancer burden when setting target Hb and ESA dose, respectively; 32 % answered that cancer history was not relevant. Here, GSTM1 is linked to anemia (phenotype).